For life sciences companies, public disclosures can significantly influence investor confidence, company valuation, and market perception. Updates related to clinical trials, regulatory submissions, manufacturing operations, and product approvals are often among the most closely watched communications an organization makes.
Now, a new development is placing even greater focus on the accuracy and consistency of those disclosures.
A new Memorandum of Understanding between the FDA and the SEC establishes a formal framework for information sharing between the two agencies. While the FDA and SEC have historically coordinated on matters involving public companies, the agreement formalizes that collaboration, creating a more structured process for information exchange and reinforcing regulatory scrutiny of disclosures related to FDA-regulated products, clinical developments, and other regulated activities.
For life sciences organizations, the message is clear: disclosure readiness is becoming indispensable.
Greater Visibility into the Information Behind Public Statements
According to the MOU, the FDA and SEC may exchange information related to FDA-regulated companies, including matters involving product development, clinical trials, manufacturing operations, inspections, supply chains, and other regulatory activities.
While the agreement does not create new disclosure requirements, it further underscores the importance of ensuring public statements accurately reflect underlying facts and regulatory developments.
This is particularly important for life sciences companies, where key business milestones often depend on FDA feedback, clinical outcomes, manufacturing readiness, or commercialization progress. Information disclosed to investors may be evaluated against a broader set of records and communications available to regulators.
As a result, organizations may face increased pressure to demonstrate that public disclosures are supported by accurate, complete, and well-documented information.
Why Disclosure Readiness Matters More Than Ever
Life sciences companies routinely manage large volumes of highly sensitive information across legal, regulatory, finance, investor relations, clinical, and executive teams.
When a material event occurs, organizations must often move quickly to gather supporting documentation, validate facts, align stakeholders, and prepare disclosures for investors, regulators, or transaction participants.
The challenge is not simply creating disclosures. It's maintaining confidence in the information behind them.
Questions organizations increasingly need to answer include:
- Can we quickly access supporting documentation when needed?
- Are stakeholders working from the same information?
- Is there a documented record of reviews and approvals?
- Can we efficiently support due diligence requests from external parties including subpoenas or requests from regulators?
- Do we have secure controls around highly sensitive information?
In today's environment, strong disclosure practices start with strong information management practices.
Building a Defensible Foundation for Due Diligence and Disclosure
As regulatory scrutiny increases, life sciences organizations should consider whether their existing processes provide sufficient visibility, control, and accountability for managing critical information.
Secure virtual data rooms can help organizations establish a more centralized and defensible approach to information management.
By bringing sensitive documents, review workflows, and key stakeholders together in a secure environment, teams can reduce reliance on fragmented file repositories, email chains, and disconnected systems that make it difficult to establish a clear record of information and decision-making.
For organizations preparing for financing events, mergers and acquisitions, strategic partnerships, IPOs, or ongoing public company obligations, these capabilities can play an important role in supporting disclosure readiness.
How DFIN Helps Life Sciences Companies Across the Corporate Lifecycle
Maintaining disclosure readiness across critical business moments requires organizations to securely manage sensitive information while supporting accurate, controlled financial reporting. DFIN provides solutions to help life sciences teams address these needs at different stages of the corporate lifecycle.
DFIN’s Venue® virtual data room (VDR) helps organizations securely manage confidential information while supporting the due diligence, regulatory, and disclosure processes that accompany major business and corporate milestones. Whether preparing for a financing event, strategic transaction, or IPO, Venue provides a centralized environment for securely organizing and sharing critical information with internal and external stakeholders.
With Venue, organizations can:
- Centralize critical information. Maintain a single source of truth for legal, regulatory, financial, and operational documentation.
- Enhance security and control. Protect sensitive information through granular permissions and controlled access for internal and external stakeholders.
- Improve due diligence efficiency. Enable advisors, auditors, investors, and other authorized parties to securely access information while reducing administrative burdens.
- Simplify global collaboration. For organizations conducting multinational clinical trials, partnering with global stakeholders, or managing cross-border transactions, Venue's AI-powered translation capabilities help streamline access to information across languages while maintaining security and efficiency.
For life sciences organizations navigating ongoing reporting obligations, DFIN ActiveDisclosure helps teams simplify financial reporting, improve accuracy, and maintain compliance through a purpose-built, centralized, and collaborative platform, paired with dedicated expertise. ActiveDisclosure helps financial reporting teams navigate complex reporting requirements with greater accuracy, control, and confidence.
With ActiveDisclosure, organizations can:
- Improve accuracy and control. Use version control, workflow management, and structured review processes to support reporting consistency and greater control throughout the reporting process.
- Streamline disclosure management. Reporting automation, collaboration tools, and disclosure management capabilities help teams reduce manual effort across recurring financial and SEC reporting workflows.
- Combine technology with expertise. Pair purpose-built reporting software with DFIN reporting, SEC filing, and regulatory expertise, along with implementation support, ongoing services and workflow guidance.
Preparing for the Next Level of Regulatory Scrutiny
The FDA-SEC MOU reflects a broader reality for life sciences companies: regulators, investors, boards, and other stakeholders continue to place a premium on transparency, accuracy, and timely disclosure.
Organizations that can efficiently manage sensitive information and support disclosures with well-documented records will be better positioned to navigate regulatory scrutiny, facilitate due diligence, and instill confidence among stakeholders.
As regulatory expectations continue to evolve, disclosure readiness is no longer simply a compliance exercise. It's a business imperative.
Explore how DFIN can support disclosure readiness across critical corporate milestones, with Venue for secure information management and due diligence, and ActiveDisclosure for ongoing financial reporting.
